Enhanced Oncolytic Adenovirus for Kidney Cancer Treatment Shows Promising Results

Strategic Insights -

Researchers at the University of Helsinki have developed an infectivity-enhanced, dual-targeted, and antiangiogenic oncolytic adenovirus for treating kidney cancer. The virus, Ad5/3-9HIF-Delta24-VEGFR-1-Ig, has shown improved specificity and antitumor effect in murine kidney cancer models. The study, published in Gene Therapy, demonstrated that the virus resulted in antitumor efficacy in a subcutaneous in vivo model and significantly enhanced survival in an intraperitoneally disseminated kidney cancer model.

Key Takeaways:

  • The Ad5/3-9HIF-Delta24-VEGFR-1-Ig virus showed improved specificity and antitumor effect in murine kidney cancer models.
  • The virus was designed to target renal cancer cells using a novel in vivo dual luciferase-imaging system.
  • The study demonstrated that the virus resulted in antitumor efficacy in a subcutaneous in vivo model.
  • Vascular endothelial growth factor receptor 1-Ig expression and a concurrent antiangiogenic effect were confirmed in the subcutaneous model.
  • Significantly enhanced survival was observed in the intraperitoneally disseminated kidney cancer model compared to control viruses.
  • The researchers concluded that a targeted, antiangiogenic, oncolytic adenovirus might be a valuable agent for testing in kidney cancer patients.
  • The study was conducted by K. Guse and colleagues at the University of Helsinki, Institute for Molecular Medicine.
  • The Ad5/3-9HIF-Delta24-VEGFR-1-Ig virus was constructed using a 5/3-serotype chimera capsid modification for kidney cancer specificity.

Statistics:

  • 16(8) was the issue number in which the study was published in Gene Therapy.
  • 1009-20 were the pages on which the study was published in Gene Therapy.
  • 2009 was the year in which the study was published.
  • 345 Park Avenue South was the address of the Nature Publishing Group in New York, NY.
  • 10010-1707 was the postal code of the Nature Publishing Group in New York, NY.
  • 8 was the reference number for the study in the Cancer Gene Therapy Week article.
  • 9 was the year in which the Copyright notice was issued.

Sources:

  • Guse, K., et al. (2009). Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment. Gene Therapy, 16(8), 1009-20.
  • Cancer Gene Therapy Week (2009). Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment. NewsRx.com.